# Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

> **NCT03677557** · PHASE4 · UNKNOWN · sponsor: **Ottawa Hospital Research Institute** · enrollment: 30 (estimated)

## Conditions studied

- Primary Immunodeficiency Disease
- Secondary Immunodeficiency

## Interventions

- **DRUG:** 16,5% Cutaquig

## Key facts

- **NCT ID:** NCT03677557
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-19
- **Primary completion:** 2021-08-31
- **Final completion:** 2021-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03677557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03677557, "Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03677557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*